mithramycin   Click here for help

GtoPdb Ligand ID: 8394

Synonyms: aureolic acid | Mithracin® | mithramycin A | MMA
Approved drug PDB Ligand
mithramycin is an approved drug (FDA (1970))
Comment: We show one representation of mithramycin here. As a natural product there are alternate chemical structures due to the complex stereochemistry. Also known as plicamycin, the compound has been used clinically as an antineoplastic antibacterial (produced by Streptomyces plicatus).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 21
Hydrogen bond donors 11
Rotatable bonds 15
Topological polar surface area 358.2
Molecular weight 1084.47
XLogP -0.39
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(C1Cc2cc3cc(OC4OC(C)C(C(C4)OC4CC(O)C(C(O4)C)O)O)c(c(c3c(c2C(=O)C1OC1OC(C)C(C(C1)OC1OC(C)C(C(C1)OC1OC(C)C(C(C1)(C)O)O)O)O)O)O)C)C(=O)C(C(O)C)O
Isomeric SMILES CO[C@@H]([C@@H]1Cc2cc3cc(O[C@@H]4O[C@H](C)[C@H]([C@@H](C4)O[C@H]4C[C@@H](O)[C@@H]([C@H](O4)C)O)O)c(c(c3c(c2C(=O)[C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H](C1)O[C@@H]1O[C@H](C)[C@@H]([C@@H](C1)O[C@@H]1O[C@H](C)[C@H]([C@@](C1)(C)O)O)O)O)O)O)C)C(=O)[C@H]([C@H](O)C)O
InChI InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1
InChI Key CFCUWKMKBJTWLW-BKHRDMLASA-N
No information available.
Summary of Clinical Use Click here for help
Before withdrawl from the market, this compound was used in the treatment of testicular cancer [1], Paget’s disease of bone, hypercalcemia and hypercalciuria.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Mithramycin binds to DNA and prevents association of transcriptional activators at GC-rich binding sites [2]. Mithramycin inhibits histone methyltransferase (HMT) enzyme activity in lung cancer cells [3], and is effective against SETDB1 HMT protein overexpression which drives tumorigenesis in non-small and small lung cancer cell lines and primary tumours [4]. The drug is also effective in inhibiting aberrant HMT-induced histone H3 (K9) trimethylation in Huntington's disease (HD) and may therefore present a novel neuroprotective mechanism for treating HD [5].